Contribution of polymorphism in codon 72 of TP53 gene to laryngeal cancer in Polish patients

Oral Oncology

Volumn 45, Issue 8, 2009, Pages 683-686

  Zemleduch, Tomasz ^a   Lianeri, Margarita ^a   Rydzanicz, Małgorzata ^b   Gajecka, Marzena ^b   Szyfter, Krzysztof ^a,b   Jagodziński, Paweł P ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b INSTITUTE OF HUMAN GENETICS   (Poland)

Author keywords

Arg72Pro TP53; Laryngeal cancer; PCR RFLP; Polymorphism

Indexed keywords

PROTEIN P53;

ADULT; ALLELE; AMINO ACID SUBSTITUTION; ARTICLE; CANCER RISK; CODON; CONTROLLED STUDY; DNA POLYMORPHISM; GENOTYPE; HUMAN; LARYNX CANCER; MAJOR CLINICAL STUDY; MALE; POLAND; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

AGED; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; CODON; GENES, P53; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LARYNGEAL NEOPLASMS; MALE; MIDDLE AGED; POLAND; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; RISK; TUMOR SUPPRESSOR PROTEIN P53;

EID: 67650494693     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2008.10.009     Document Type: Article

References (46)

1. Bray F., Sankila R., Ferlay J., and Parkin D.M. Estimates of cancer incidence and mortality in Europe in 1995. Eur J Cancer 38 (2002) 99-166
2. Sapkota A, Hsu CC, Zaridze D, Shangina O, Szeszenia-Dabrowska N, Mates D, et al. Dietary risk factors for squamous cell carcinoma of the upper aerodigestive tract in central and eastern Europe. Cancer Causes Control 10.1007/s10552-008-9183-0.
3. Freedman N.D., Abnet C.C., Leitzmann M.F., Hollenbeck A.R., and Schatzkin A. Prospective investigation of the cigarette smoking-head and neck cancer association by sex. Cancer 110 (2007) 1593-1601
4. Brockmöller J., Cascorbi I., Henning S., Meisel C., and Roots I. Molecular genetics of cancer susceptibility. Pharmacology 61 (2000) 212-227
5. Szyfter K., Szmeja Z., Szyfter W., Hemminki K., Banaszewski J., and Jaskuła-Sztul R. Molecular and cellular alterations in tobacco smoke-associated larynx cancer. Mutat Res 445 (1999) 259-274
6. Bradford C.R. Predictive factors in head and neck cancer. Hematol Oncol Clin North Am 13 (1999) 777-785
7. Chomchai J.S., Du W., Sarkar F.H., Li Y.W., Jacobs J.R., Ensley J.F., et al. Prognostic significance of p53 gene mutations in laryngeal cancer. Laryngoscope 109 (1999) 455-459
8. Salam M., Rockett J., and Morris A. The prevalence of different human papillomavirus types and p53 mutations in laryngeal carcinomas: is there a reciprocal relationship. Eur J Surg Oncol 21 (1995) 290-296
9. Anwar K., Nakakuki K., Imai H., Naiki H., and Inuzuka M. Over-expression of p53 protein in human laryngeal carcinoma. Int J Cancer 53 (1993) 952-956
10. Zhao X., Li F.C., Li Y.H., Fu W.N., Huang D.F., Ye Y., et al. Mutation of p53 and overexpression of STK15 in laryngeal squamous-cell carcinoma. Zhonghua Zhong Liu Za Zhi 27 (2005) 134-137
11. Levine A.J. p53, the cellular gatekeeper for growth and division. Cell 88 (1997) 323-331
12. Buchman V.L., Chumakov P.M., Ninkina N.N., Samarina O.P., and Georgiev G.P. A variation in the structure of the protein-coding region of the human p53 gene. Gene 70 (1988) 245-252
13. Matlashewski G.J., Tuck S., Pim D., Lamb P., Schneider J., and Crawford L.V. Primary structure polymorphism at amino acid residue 72 of human p53. Mol Cell Biol 7 (1987) 961-963
14. Dumont P., Leu J.I., Della Pietra III A.C., George D.L., and Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nature Genetic 33 (2003) 357-365
15. Pim D., and Banks L. p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int J Cancer 108 (2004) 196-199
16. Marin M.C., Jost C.A., Brooks L.A., Irwin M.S., O'Nions J., Tidy J.A., et al. A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat Genetic 25 (2000) 47-54
17. Hiyama T., Yoshihara M., Tanaka S., and Chayama K. Genetic polymorphisms and head and neck cancer risk. Int J Oncol 32 (2008) 945-973
18. Van Heemst D., Mooijaart S.P., Beekman M., Schreuder J., de Craen A.J., Brandt B.W., et al. Long life study group. Variation in the human TP53 gene affects old age survival and cancer mortality. Exp Gerontol 40 (2005) 11-15
19. Zhou Y., Li N., Zhuang W., Liu G.J., Wu T.X., Yao X., et al. p53 codon 72 polymorphism and gastric cancer: a meta-analysis of the literature. Int J Cancer 121 (2007) 1481-1486
20. Koushik A., Platt R.W., and Franco E.L. p53 codon 72 polymorphism and cervical neoplasia: a meta-analysis. Cancer Epidemiol Biomarkers Prev 13 (2004) 11-22
21. Matakidou A., Eisen T., and Houlston R.S. TP53 polymorphisms and lung cancer risk: a systematic review and meta-analysis. Mutagenesis 18 (2003) 377-385
22. Irarrazabal C.E., Rojas C., Aracena R., Marquez C., and Gil L. Chilean pilot study on the risk of lung cancer associated with codon 72 polymorphism in the gene of protein p53. Toxicol Lett 144 (2003) 69-76
23. Lee J.M., Lee Y.C., Yang S.Y., Shi W.L., Lee C.J., Luh S.P., et al. Genetic polymorphisms of p53 and GSTP1, but not NAT2, are associated with susceptibility to squamous-cell carcinoma of the esophagus. Int J Cancer 89 (2000) 458-464
24. Hiyama T., Tanaka S., Kitadai Y., Ito M., Sumii M., Yoshihara M., et al. p53 codon 72 polymorphism in gastric cancer susceptibility in patients with Helicobacter pylori-associated chronic gastritis. Int J Cancer 100 (2002) 304-308
25. Sjalander A., Birgander R., Hallmans G., Cajander S., Lenner P., Athlin L., et al. p53 polymorphisms and haplotypes in breast cancer. Carcinogenesis 17 (1996) 1313-1316
26. Tsai M.H., Lin C.D., Hsieh Y.Y., Chang F.C., Tsai F.J., Chen W.C., et al. Prognostic significance of the proline form of p53 codon 72 polymorphism in nasopharyngeal carcinoma. Laryngoscope 112 (2002) 116-119
27. Kuroda Y., Tsukino H., Nakao H., Imai H., and Katoh T. p53 codon 72 polymorphism and urothelial cancer risk. Cancer Lett 189 (2003) 77-83
28. Suzuki K., Matsui H., Ohtake N., Nakata S., Takei T., Nakazato H., et al. A p53 codon 72 polymorphism associated with prostate cancer development and progression in Japanese. J Biomed Sci 10 (2003) 430-435
29. Zhu Z.Z., Cong W.M., Liu S.F., Dong H., Zhu G.S., and Wu M.C. Homozygosity for Pro of p53 Arg72Pro as a potential risk factor for hepatocellular carcinoma in Chinese population. World J Gastroenterol 11 (2005) 289-292
30. Yang M., Guo Y., Zhang X., Miao X., Tan W., Sun T., et al. Interaction of P53 Arg72Pro and MDM2 T309G polymorphisms and their associations with risk of gastric cardia cancer. Carcinogenesis 28 (2007) 1996-2001
31. Perfumo C., Bonelli L., Menichini P., Inga A., Gismondi V., Ciferri E., et al. Increased risk of colorectal adenomas in Italian subjects carrying the p53 PIN3 A2-Pro72 haplotype. Digestion 74 (2006) 228-235
32. Szymanowska A., Jassem E., Dziadziuszko R., Borg A., Limon J., Kobierska-Gulida G., et al. Increased risk of non-small cell lung cancer and frequency of somatic TP53 gene mutations in Pro72 carriers of TP53 Arg72Pro polymorphism. Lung Cancer 52 (2006) 9-14
33. Sreeja L., Syamala V., Raveendran P.B., Santhi S., Madhavan J., and Ankathil R. p53 Arg72Pro polymorphism predicts survival outcome in lung cancer patients in Indian population. Cancer Invest 26 (2008) 41-46
34. Gottschlich S., Maune S., Preugschat J., Hoffmann M., Werner J.A., Maass J.D., et al. p53 analysis of laryngeal cancer in exon 4 to 9. Anticancer Res 20 (2000) 2613-2616
35. Dakouras A., Nikiteas N., Papadakis E., Perakis M., Valis D., Rallis G., et al. p53Arg72 homozygosity and its increased incidence in left-sided sporadic colorectal adenocarcinomas, in a Greek-Caucasian population. Anticancer Res 28 (2008) 1039-1043
36. Costa S., Pinto D., Pereira D., Rodrigues H., Cameselle-Teijeiro J., Medeiros R., et al. Importance of TP53 codon 72 and intron 3 duplication 16bp polymorphisms in prediction of susceptibility on breast cancer. BMC Cancer 8 (2008) 32-39
37. Sourvinos G., Rizos E., and Spandidos D.A. p53 codon 72 polymorphism is linked to the development and not the progression of benign and malignant laryngeal tumours. Oral Oncol 37 (2001) 572-578
38. Storey A., Thomas M., Kalita A., Harwood C., Gardiol D., Mantovani F., et al. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 393 (1998) 229-234
39. Frazer K.A., Ballinger D.G., Cox D.R., Hinds D.A., Stuve L.L., Gibbs R.A., et al. A second generation human haplotype map of over 3.1 1 million SNPs. Nature 449 (2007) 851-861
40. Meulmeester E., and Jochemsen A.G. p53: a guide to apoptosis. Curr Cancer Drug Targets 8 (2008) 87-97
41. Pinto G.R., Yoshioka F.K., Silva R.L., Clara C.A., Santos M.J., Almeida J.R., et al. Prognostic value of TP53 Pro47Ser and Arg72Pro single nucleotide polymorphisms and the susceptibility to gliomas in individuals from Southeast Brazil. Genet Mol Res 7 (2008) 207-216
42. Minaguchi T., Kanamori Y., Matsushima M., Yoshikawa H., Taketani Y., and Nakamura Y. No evidence of correlation between polymorphism at codon 72 of p53 and risk of cervical cancer in Japanese patients with human papillomavirus 16/18 infection. Cancer Res 58 (1998) 4585-4586
43. McWilliams J.E., Evans A.J., Beer T.M., Andersen P.E., Cohen J.I., Everts E.C., et al. Genetic polymorphisms in head and neck cancer risk. Head Neck 22 (2000) 609-617
44. Matakidou A., El Galta R., Webb E.L., Rudd M.F., Bridle H., Eisen T., et al. ConsortiumLack of evidence that p53 Arg72Pro influences lung cancer prognosis: an analysis of survival in 619 female patients. Lung Cancer 57 (2007) 207-212
45. Thomas M., Kalita A., Labrecque S., Pim D., Banks L., and Matlashewski G. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol 19 (1999) 1092-1100
46. Leu J.I., Dumont P., Hafey M., Murphy M.E., and George D.L. Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcl1 complex. Nat Cell Biol 6 (2004) 443-450